Abdominal metastases of primary extremity soft tissue sarcoma: A systematic review

Table 1 Original articles (n = 6) analysing incidence of abdominal/retroperitoneal metastases in patients with extremity soft tissue sarcoma

Ref.	Topic	Patients		(Prevalent) Histological subtype(s)	Chemotherapy/ radiotherapy	Outcome (after diagnosis of metastasis)
		Total number of STS (n), of whom eSTS, n (%)	Of whom eSTS with AM/RM, n (%)
Thompson et al[16], 2015	Diagnostic pathway	140 (100)	7 (5.0) AM	Epithelioid sarcoma, leiomyosarcoma, liposarcoma, synovial sarcoma	N/A	N/A
King et al[9], 2009	Diagnostic pathway, outcome	124 (100)	7 (5.6) AM	MPNST, leiomyosarcoma, myxofibrosarcoma, pleomorphic sarcoma	N/A	21% mortality rate (n = 21/124)
Gorelik et al[6], 2018	Diagnostic pathway	33 (100)	4 (12.1) AM	Myxoid liposarcoma	89% of patients with metastases (including others than AM) received neoadj. RTX 22% received adj. RTX for primary tumour	N/A
Behranwala et al[8], 2004	Therapeutic approach	2127 (100)	19 (0.9) AM	Myxoid liposarcoma, leiomyosarcoma	CTX + RTX in 3 patients, and CTX or RTX in 1 patient each following resection of AM	Median OS: 12 mo
Ogose et al[11], 2000	Therapeutic approach	282 (100)	24 (8.5) AM	Liposarcoma	None of patients with AM received RTX or CTX	Mean OS (liver/GI metastases): 4.6 mo; Mean OS (pancreatic metastasis): 3.3 mo
Sheah et al[7], 2008	Diagnostic pathway	112 (100)	9 (8.0) AM; 2 (1.8) RM	Myxoid liposarcoma	N/A	N/A

AM: Abdominal metastasis; AWD: Alive with disease; DOD: Dead of disease; eSTS: Extremity soft tissue sarcoma; NED: No evidence of disease; OS: Overall survival; PFS: Progression-free survival; STS: Soft tissue sarcoma; CTX: Chemotherapy; RTX: Radiotherapy; N/A: Not applicable.